David Duggan
Translational Genomics Research Institute, USA
Biography
David Duggan is a leading translational scientist and market/technical analyst with 26 years of scientific expertise and nearly a decade of experience advising equity management firms on many of the leading genomics and personalized medicine companies. Research in his laboratory focuses on the inherited basis of human disease and germline DNA risk assessment with an emphasis on cancer predisposition. High-throughput, state-of-the-art technologies including genotyping and next generation sequencing were often paired with population- and familial-based study designs. His laboratory has generated genetic/genomic data on >300,000 samples; published >150 peer-reviewed manuscripts; 6 invited reviews; 3 book chapters; and, co-edited a book on Oncogenomics: Molecular Approaches to Cancer. Dr. Duggan is a current and past member of the steering committees for several National Institutes of Health (USA) funded consortiums. He has been an invited participant in several national and international grant review panels; and, has been an invited participant in the scientific advisory committees for two leading genomic technology companies. Dr. Duggan received his Ph.D. in human genetics from the University of Pittsburgh and obtained his post-doctoral training at the National Human Genome Research Institute, National Institutes of Health (USA).
Abstract
Abstract : Unlocking the Potential of Precision Genomic Medicine: Examples from Oncology